TY - JOUR
T1 - Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis (methylene)selenocyanate
AU - Rao, Chinthalapally V.
AU - Cooma, Indranie
AU - Rosa Rodriguez, Jose G.
AU - Simi, Barbara
AU - El-Bayoumy, Karam
AU - Reddy, Bandaru S.
PY - 2000
Y1 - 2000
N2 - Epidemiological and experimental studies have suggested that dietary supplementation with selenium can inhibit the development of cancers at several organ sites. We have consistently shown that 1,4-phenylene bis(methylene) selenocyanate (p-XSC) is a highly effective cancer chemopreventive agent against the development of chemically induced cancers in several laboratory animal species. This is the first report describing the preventive effects of p-XSC in an animal model of familial adenomatous polyposis (FAP) containing a germline mutation of the APC gene. Six-week old male (heterozygous) C57BL/6J-APC(min) or wild-type mice were fed high fat diets containing 0, 10 or 20 p.p.m. p-XSC. After 80 days, the mice were killed and their intestines were excised and evaluated for polyps. Multiple samples were also harvested from normal appearing small intestine and colon for molecular analysis. Both the mucosa and polyps from the intestine and colon were assayed for β-catenin, cyclooxygenase (COX)-2 expression and COX isoform activities. Administration of p-XSC in the diet significantly decreased the rate of formation of small intestinal tumors (P < 0.0001) and colon tumors (P < 0.002) in APC(min) mice. p-XSC produced a dose-dependent inhibition of tumors in both small intestine (P < 0.0001) and colon (P < 0.035). Mice fed 20 p.p.m. p-XSC had significantly lower levels of β-catenin expression and COX-2 activity in polyps. These observations demonstrate for the first time that the synthetic organoselenium compound p-XSC possesses antitumor activity against genetically predisposed neoplastic lesions, such as FAP. While the exact mechanism(s) for this antitumor activity of p-XSC remains to be elucidated, it appears that modulation of β-catenin expression and COX-2 activity is associated with inhibition of intestinal polyps.
AB - Epidemiological and experimental studies have suggested that dietary supplementation with selenium can inhibit the development of cancers at several organ sites. We have consistently shown that 1,4-phenylene bis(methylene) selenocyanate (p-XSC) is a highly effective cancer chemopreventive agent against the development of chemically induced cancers in several laboratory animal species. This is the first report describing the preventive effects of p-XSC in an animal model of familial adenomatous polyposis (FAP) containing a germline mutation of the APC gene. Six-week old male (heterozygous) C57BL/6J-APC(min) or wild-type mice were fed high fat diets containing 0, 10 or 20 p.p.m. p-XSC. After 80 days, the mice were killed and their intestines were excised and evaluated for polyps. Multiple samples were also harvested from normal appearing small intestine and colon for molecular analysis. Both the mucosa and polyps from the intestine and colon were assayed for β-catenin, cyclooxygenase (COX)-2 expression and COX isoform activities. Administration of p-XSC in the diet significantly decreased the rate of formation of small intestinal tumors (P < 0.0001) and colon tumors (P < 0.002) in APC(min) mice. p-XSC produced a dose-dependent inhibition of tumors in both small intestine (P < 0.0001) and colon (P < 0.035). Mice fed 20 p.p.m. p-XSC had significantly lower levels of β-catenin expression and COX-2 activity in polyps. These observations demonstrate for the first time that the synthetic organoselenium compound p-XSC possesses antitumor activity against genetically predisposed neoplastic lesions, such as FAP. While the exact mechanism(s) for this antitumor activity of p-XSC remains to be elucidated, it appears that modulation of β-catenin expression and COX-2 activity is associated with inhibition of intestinal polyps.
UR - http://www.scopus.com/inward/record.url?scp=0034053147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034053147&partnerID=8YFLogxK
U2 - 10.1093/carcin/21.4.617
DO - 10.1093/carcin/21.4.617
M3 - Article
C2 - 10753194
AN - SCOPUS:0034053147
SN - 0143-3334
VL - 21
SP - 617
EP - 621
JO - Carcinogenesis
JF - Carcinogenesis
IS - 4
ER -